No Data
No Data
Raymond James Initiates Eupraxia Pharmaceuticals(EPRX.US) With Buy Rating, Announces Target Price $12
Raymond James Sticks to Their Buy Rating for Eupraxia Pharmaceuticals (EPRX)
Here's Why We're Watching Eupraxia Pharmaceuticals' (TSE:EPRX) Cash Burn Situation
Eupraxia Pharmaceuticals | 6-K: Report of foreign private issuer (related to financial reporting)
Eupraxia Pharmaceuticals Reports FY24 EPS (76c), Consensus (63c)
Eupraxia Pharmaceuticals 4Q Loss $7.5M >EPRX.T